ChEMBL ligand: CHEMBL383322 (CD-11301, CD11301, R-848, R848, Resiquimod, S-28463)
Oxidized purine nucleoside triphosphate hydrolase in Human [ChEMBL: CHEMBL3708265] [UniProtKB: P36639] There should be some charts here, you may need to enable JavaScript!
TLR7/Toll-like receptor 7 in Human [ChEMBL: CHEMBL5936] [GtoPdb: 1757] [UniProtKB: Q9NYK1] There should be some charts here, you may need to enable JavaScript!
TLR8/Toll-like receptor 8 in Human [ChEMBL: CHEMBL5805] [GtoPdb: 1758] [UniProtKB: Q9NR97] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
Oxidized purine nucleoside triphosphate hydrolase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3708265] [UniProtKB: P36639]
ChEMBL	Inhibition of MTH1 (unknown origin) using 8-oxo-dGTP as substrate preincubated for 15 mins followed by substrate addition and measured after 20 mins by PPiLight detection reagent based luminescence assay	B	5.69	pIC50	2056	nM	IC50	J Med Chem (2016) 59: 2346-2361 [PMID:26878898]
TLR7/Toll-like receptor 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5936] [GtoPdb: 1757] [UniProtKB: Q9NYK1]
ChEMBL	Agonist activity at human TLR7 receptor	B	5.82	pEC50	1500	nM	EC50	Eur J Med Chem (2021) 218: 113356-113356 [PMID:33773287]
ChEMBL	Agonist activity at human TLR-7 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay	B	5.82	pEC50	1500	nM	EC50	J Med Chem (2014) 57: 339-347 [PMID:24383475]
ChEMBL	Agonist activity at TLR7 (unknown origin)	B	5.82	pEC50	1500	nM	EC50	J Med Chem (2023) 66: 6437-6462 [PMID:37163340]
ChEMBL	Activation of TLR7 (unknown origin)	B	5.82	pEC50	1500	nM	EC50	Eur J Med Chem (2020) 193: 112238-112238 [PMID:32203790]
ChEMBL	Agonist activity at human TLR7 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay	F	5.85	pEC50	1400	nM	EC50	ACS Med Chem Lett (2012) 3: 501-504 [PMID:22837811]
GtoPdb	-	-	5.87	pEC50	1340	nM	EC50	Nat Immunol (2002) 3: 196-200 [PMID:11812998]; Nat Immunol (2002) 3: 499 [PMID:12032557]; ACS Med Chem Lett (2017) 8: 1148-1152 [PMID:29152046]
ChEMBL	Agonist activity at human TLR7 expressed in HEK cells after 8 to 12 hrs by NFkappaB/SEAP reporter gene assay	B	5.87	pEC50	1340	nM	EC50	ACS Med Chem Lett (2017) 8: 1148-1152 [PMID:29152046]
ChEMBL	Agonist activity at TLR7 in human PBMC assessed as induction of IN-12 stimulation	B	5.9	pEC50	1259	nM	EC50	J Med Chem (2016) 59: 2346-2361 [PMID:26878898]
ChEMBL	Reporter Assay: For TLR8 and TLR7 activity testing, HEK-Blue human TLR8 or TLR7 cells, respectively, (Invivogen, San Diego, Calif., USA) transfected with a SEAP reporter (secreted embryonic alkaline phosphatase) construct were used, in which the reporter expression is regulated by the NF-κB promoter upon stimulation for 24 hr. The reporter activity was determined using Quanti Blue kit (Invivogen, San Diego, Calif., USA) at a wavelength of 640 nm.	B	6.12	pEC50	760	nM	EC50	US-9334268-B2. 4-amino-imidazoquinoline compounds (2016)
ChEMBL	Agonist activity at human TLR7 expressed in HEK293 cells assessed as induction of NFKappaB activity after 24 hrs by SEAP reporter gene assay	B	6.12	pEC50	750	nM	EC50	Bioorg Med Chem Lett (2020) 30: 126984-126984 [PMID:32001135]
ChEMBL	Agonist activity at TLR7 in human Ramos-blue cells assessed as increase in NFkappaB activation incubated for 72 hrs by quanti-blue/SEAP reporter gene based assay	B	6.21	pEC50	616	nM	EC50	ACS Med Chem Lett (2023) 14: 1358-1368 [PMID:37849530]
ChEMBL	TLR7 Agonist Activity Assay: Engineered human embryonic kidney blue cells (HEK-Blue™ TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO2. Compounds (100 nl) were dispensed into wells containing the HEK-Blue™ TLR cells and the treated cells were incubated at 37° C., 5% CO2. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue™ reagent (Invivogen) was added to each well, incubated for 30 min (37° C., 5% CO2) and SEAP levels measured using an Envision plate reader (OD=620 nm). The half maximal effective concentration values (EC50; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.	B	6.38	pEC50	420	nM	EC50	US-10981914-B2. Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor (2021)
ChEMBL	TLR7 Agonist Activity Assay: Engineered human embryonic kidney blue cells (HEK-Blue TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO2. Compounds (100 nl) were dispensed into wells containing the HEK-Blue TLR cells and the treated cells were incubated at 37° C., 5% CO2. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue reagent (Invivogen) was added to each well, incubated for 30 min (37° C., 5% CO2) and SEAP levels measured using an Envision plate reader (OD=620 nm). The half maximal effective concentration values (EC50; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.	B	6.38	pEC50	420	nM	EC50	US-10457681-B2. Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor (2019)
ChEMBL	TLR7 Agonist Activity Assay: Engineered human embryonic kidney blue cells (HEK-Blue TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO2. Compounds (100 nl) were dispensed into wells containing the HEK-Blue™ TLR cells and the treated cells were incubated at 37° C., 5% CO2. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue reagent (Invivogen) was added to each well, incubated for 30 min (37° C., 5% CO2) and SEAP levels measured using an Envision plate reader (OD=620 nm). The half maximal effective concentration values (EC50; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.	B	6.38	pEC50	420	nM	EC50	US-10487084-B2. Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor (2019)
ChEMBL	TLR7 Agonist Activity Assay: Engineered human embryonic kidney blue cells (HEK-Blue™ TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO2. Compounds (100 nl) were dispensed into wells containing the HEK-Blue™ TLR cells and the treated cells were incubated at 37° C., 5% CO2. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue™ reagent (Invivogen) was added to each well, incubated for 30 min (37° C., 5% CO2) and SEAP levels measured using an Envision plate reader (OD=620 nm). The half maximal effective concentration values (EC50; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.	B	6.38	pEC50	420	nM	EC50	US-10508115-B2. Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor (2019)
ChEMBL	HEK-Blue TLR7 reporter assay: Engineered human embryonic kidney blue cells (HEK-Blue™ TLR cells; Invivogen) possessing a human TLR7-secreted embryonic alkaline phosphatase (SEAP) reporter transgene were suspended in a non-selective, culture medium (DMEM high-glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma)). HEK-Blue™ TLR7 cells were added to each well of a 384-well tissue-culture plate (15,000 cells per well) and incubated 16-18 h at 37° C., 5% CO2. Compounds (100 nl) were dispensed into wells containing the HEK-Blue™ TLR cells and the treated cells were incubated at 37° C., 5% CO2. After 18 h treatment ten microliters of freshly-prepared Quanti-Blue™ reagent (Invivogen) was added to each well, incubated for 30 min (37° C., 5% CO2) and SEAP levels measured using an Envision plate reader (OD=620 nm). The half maximal effective concentration values (EC50; compound concentration which induced a response halfway between the assay baseline and maximum) were calculated.	B	6.48	pEC50	330	nM	EC50	US-10919895-B2. Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor (2021)
ChEMBL	Agonist activity at human TLR7 in HEK-Blue hTLR7 cells assessed as increase in inducible SEAP level incubated for overnight by QUANTI-Blue reagent based assay	B	6.51	pEC50	310	nM	EC50	J Med Chem (2024) 67: 8346-8360 [PMID:38741265]
ChEMBL	Agonist activity at human TLR7 expressed in HEK293 cells coexpressing pNiFty2-SEAP reporter by reporter gene assay	F	6.58	pEC50	260.1	nM	EC50	J Med Chem (2010) 53: 2964-2972 [PMID:20232824]
ChEMBL	Agonist activity at human TLR7 expressed in HEK-Blue cells assessed as induction of NFkappaB activation by measuring increase in SEAP level by SEAP reporter gene-based UV-vis absorbance method	B	6.6	pEC50	250	nM	EC50	Bioorg Med Chem Lett (2020) 30: 126788-126788 [PMID:31784317]
ChEMBL	Agonist activity at human TLR7 expressed in HEK293 cells incubated for 6 to 16 hrs by SEAP reporter gene assay	B	7.12	pEC50	75	nM	EC50	J Med Chem (2021) 64: 7507-7532 [PMID:34048243]
TLR8/Toll-like receptor 8 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5805] [GtoPdb: 1758] [UniProtKB: Q9NR97]
ChEMBL	Reporter Assay: For TLR8 and TLR7 activity testing, HEK-Blue human TLR8 or TLR7 cells, respectively, (Invivogen, San Diego, Calif., USA) transfected with a SEAP reporter (secreted embryonic alkaline phosphatase) construct were used, in which the reporter expression is regulated by the NF-κB promoter upon stimulation for 24 hr. The reporter activity was determined using Quanti Blue kit (Invivogen, San Diego, Calif., USA) at a wavelength of 640 nm.	B	5.02	pEC50	9600	nM	EC50	US-9334268-B2. 4-amino-imidazoquinoline compounds (2016)
ChEMBL	Agonist activity at human TLR8 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay	F	5.19	pEC50	6400	nM	EC50	ACS Med Chem Lett (2012) 3: 501-504 [PMID:22837811]
GtoPdb	-	-	5.21	pEC50	6130	nM	EC50	Nat Immunol (2002) 3: 196-200 [PMID:11812998]; Nat Immunol (2002) 3: 499 [PMID:12032557]; ACS Med Chem Lett (2017) 8: 1148-1152 [PMID:29152046]
ChEMBL	Agonist activity at human TLR8 expressed in HEK cells after 8 to 12 hrs by NFkappaB/SEAP reporter gene assay	B	5.21	pEC50	6130	nM	EC50	ACS Med Chem Lett (2017) 8: 1148-1152 [PMID:29152046]
ChEMBL	Agonist activity at human TLR8 expressed in HEK293 cells assessed as induction of NFKappaB activity after 24 hrs by SEAP reporter gene assay	B	5.23	pEC50	5870	nM	EC50	Bioorg Med Chem Lett (2020) 30: 126984-126984 [PMID:32001135]
ChEMBL	Activation of TLR8 (unknown origin)	B	5.35	pEC50	4500	nM	EC50	Eur J Med Chem (2020) 193: 112238-112238 [PMID:32203790]
ChEMBL	Agonist activity at human TLR-8 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay	B	5.35	pEC50	4500	nM	EC50	J Med Chem (2014) 57: 339-347 [PMID:24383475]
ChEMBL	Agonist activity at TLR8 (unknown origin)	B	5.35	pEC50	4500	nM	EC50	J Med Chem (2023) 66: 6437-6462 [PMID:37163340]
ChEMBL	Agonist activity at human TLR8 receptor	B	5.35	pEC50	4500	nM	EC50	Eur J Med Chem (2021) 218: 113356-113356 [PMID:33773287]
ChEMBL	Agonist activity at human TLR8 expressed in HEK293 cells incubated for 6 hrs by luciferase reporter gene assay	B	5.4	pEC50	4000	nM	EC50	J Med Chem (2016) 59: 5868-5878 [PMID:27270029]
ChEMBL	Agonist activity at human TLR8 in HEK-Blue hTLR8 cells assessed as increase in inducible SEAP level incubated for overnight by QUANTI-Blue reagent based assay	B	5.46	pEC50	3500	nM	EC50	J Med Chem (2024) 67: 8346-8360 [PMID:38741265]
ChEMBL	Agonist activity at human TLR8 expressed in HEK-Blue cells assessed as induction of NFkappaB activation by measuring increase in SEAP level by SEAP reporter gene-based UV-vis absorbance method	B	5.52	pEC50	3000	nM	EC50	Bioorg Med Chem Lett (2020) 30: 126788-126788 [PMID:31784317]
ChEMBL	Agonist activity in TLR8 (unknown origin) expressed in HEK293 cells assessed as induction of NF-kappa activation	B	5.82	pEC50	1500	nM	EC50	Eur J Med Chem (2020) 193: 112238-112238 [PMID:32203790]
ChEMBL	Agonist activity at human TLR8 expressed in HEK293 cells incubated for 6 to 16 hrs by SEAP reporter gene assay	B	6.32	pEC50	480	nM	EC50	J Med Chem (2021) 64: 7507-7532 [PMID:34048243]

ChEMBL data shown on this page come from version 36:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]